Clearing drug interferences in myeloma treatment using mass spectrometry
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Clinical Biochemistry
- Vol. 92, 61-66
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Daratumumab: a game changer in myeloma therapyThe Lancet Haematology, 2020
- Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy MonitoringThe Journal of Applied Laboratory Medicine, 2019
- Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal AntibodiesJournal of Proteome Research, 2018
- Identification of Friend or Foe: The Laboratory Challenge of Differentiating M-Proteins from Monoclonal Antibody TherapiesThe Journal of Applied Laboratory Medicine, 2017
- Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass SpectrometryClinical Chemistry, 2016
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interferenceClinical Chemistry and Laboratory Medicine (CCLM), 2016
- Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)Clinical Chemistry and Laboratory Medicine (CCLM), 2016
- Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal GammopathyJournal of Proteome Research, 2014
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003